A Phase I Study of Autologous CD19 Specific Chimeric Antigen Receptor T-cells for Therapy of Relapsed and Refractory B-cell Leukaemia and Lymphoma (The Auto-CAR19 Trial). [ 2017 - 2019 ]

Research Grant

Researchers: Dr Kenneth Micklethwaite (Principal investigator) ,  A/Pr Tracey O'Brien ,  Dr Luciano Dalla-Pozza ,  Dr Toby Trahair ,  Prof David Gottlieb
View all 6 related researchers

Brief description Most people with leukaemia and lymphoma who relapse early after chemotherapy die of their disease. Inserting special genes into immune cells can enable them to kill leukaemia and lymphoma and has led to dramatic cures, but the cost of the viral vectors used to make these cells is prohibitively expensive. We will make leukaemia and lymphoma specific immune cells from patients using an inexpensive non-viral system, then administer the immune cells to patients to assess their safety and efficacy.

Funding Amount $AUD 597,911.41

Funding Scheme Project Grants

Notes Standard Project Grant